# Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

> **NCT04730427** · PHASE1 · TERMINATED · sponsor: **Genexine, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** GX-I7
- **DRUG:** GX-I7 vehicle

## Key facts

- **NCT ID:** NCT04730427
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-24
- **Primary completion:** 2022-05-08
- **Final completion:** 2022-07-07
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04730427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04730427, "Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04730427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*